ClinicalTrials.gg
RecruitingNCT06224816M3DPREMATUpdated Apr 18, 2024

Clinical Trial for the Evaluation of Customized 3D Printed NIV Nasal Masks in Premature Infants

An interventional study of Custom 3D mask (3DM) application in neonate and Traditional mask (TM) application in neonate in Premature Lungs, sponsored by Hospital Universitario 12 de Octubre. Recruiting at 1 site in Spain. Open to participants aged 0 Days to 30 Days. Per ClinicalTrials.gov, last updated 2024-04-18.

Sponsored by Hospital Universitario 12 de Octubre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
0 Days to 30 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 73 studies in Premature Birth with a site in Spain — 16 open to participants now, 17 under way, none of them phase 3. Premature Birth · Spain.

Planned enrollment
38th of 56
60 · median 121
Started
2024
with 4 others
No phase
33 of 73
8 open now
Primary completion
2026-12
later than 12 of 16 live
Registered
63rd of 73
by date
Lead sponsor
2 of 73
Hospital Universitario 12 de Octubre

Among the 73 studies in Premature Birth with a site in Spain, this one is the 38th largest by planned enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2024, is one of 33 with no phase, reaches primary completion later than 12 of the 16 other live ones, and was the 63rd registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

16 of the 73 studies in Premature Birth with a site in Spain are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 0 Days to 30 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Premature Birth with a site in Spain, or all of them as a file.
02

Study summary

Clinical trial with crossed groups, open, masked for the evaluation of the main outcome. Inclusion of all premature infants with a birth weight less than 1500 g requiring Non-invasive Ventilation (NIV).

Premature will be randomised to start alternatively with MT or 3DM. Each patient included will be their own control at the same time, receiving each of the different mask models every 4 hours alternately. The study period will be a maximum of 7 days.

To compare the time in which preterm maintain SatO2 below 85% with the 3DM versus the traditional mask (TM) in preterm \< 1500 g. Other secondary objectives regarding ventilation enhancement will be assessed, such as the number of bradycardias, cardiorespiratory arrest and need for resuscitation in the context of apnea. Also, skin lesions of the nose resulting from the pressure applied by any of the masks (TM or 3DM) and the need for analgesia and/or sedation for pain control or discomfort will be assessed. Parental perception and satisfaction will be assessed.

Read the detailed description

Improvement and optimization of non-invasive ventilation (NIV) in preterm and low birth weight infants is essential in order to reduce morbidity. By the use of 3D printing design (3DM), these infants would be provided with customized nasal masks, according to their particular anatomical features while on NIV. This would lead to a greater stabilization of the respiratory system, decreased apnea spells, oxygen desaturation and bradycardia, less need for intubation and less skin nose injury, all of which might improve neurodevelopmental outcomes.

03

Conditions studied

  • Premature Lungs

Browse trials for

Keywords

  • Neonatology
  • Nasal mask
  • 3D printing
  • Additive manufacturing
  • Newborn
  • Premature
  • Prematurity
  • Neonate
  • Non-Invasive Ventilation (NIV)
  • Oxygen saturation
  • SolidWorks
  • 3D scanner
  • Customized device
  • Continuous positive airway pressure (CPAP)
04

Who can participate

Ages eligible
0 Days to 30 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newborn prematurity
  • Age: less than 30 days of life
  • Required respiratory support with non-invasive ventilation (NIV)
  • Premature infant has not been on NIV for more than 3 days before being included in the trial.
  • Signature of the (IC)

Exclusion criteria

Exclusion Criteria:

  • Failure to meet entry criteria
  • Cyanotic congenital heart disease diagnosis
  • Presence of serious malformations
  • Presence of airway malformations
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    3D Mask (3DM)

    Custom 3D mask (3DM) application in neonate during 4 hours. Each patient included will be their own control at the same time, receiving each of the different mask models every 4 hours alternately. The study period will be a maximum of 7 days.

    Device: Custom 3D mask (3DM) application in neonate · Device: Traditional mask (TM) application in neonate

  • Active comparator
    Traditional Mask (TM)

    Traditional Mask (TM) application in neonate during 4 hours. Each patient included will be their own control at the same time, receiving each of the different mask models every 4 hours alternately. The study period will be a maximum of 7 days.

    Device: Custom 3D mask (3DM) application in neonate · Device: Traditional mask (TM) application in neonate

Interventions

  • DeviceCustom 3D mask (3DM) application in neonate

    Premature infants with a birth weight less than 1500 g r first received 3D mask during 4 hour, then crossed over to traditional mask.

  • DeviceTraditional mask (TM) application in neonate

    Premature infants with a birth weight less than 1500 g r first received traditional mask during 4 hours, then crossed over to 3D mask.

06

What researchers measure

Primary outcomes

  1. Time in which preterm maintain SatO2 below 85%.

    To compare the time in which preterm maintain SatO2 below 85%.in the period of time that customized 3D printed nasal mask (3DM) is used versus traditional nasal mask (TM).

    Time frame: 7 days

Secondary outcomes

  1. Time in which preterm maintain bradycardias.

    To compare the time in which preterm maintain bradycardias - heart rate below 100 beats per minute - that occur in the period of time that customized 3D printed nasal mask (3DM) is used versus traditional nasal mask (TM).

    Time frame: 7 days

  2. Time in which preterm maintain SatO2 below 75%.

    To compare the time in which preterm maintain SatO2 below 75%.in the period of time that customized 3D printed nasal mask (3DM) is used versus traditional nasal mask (TM).

    Time frame: 7 days

  3. Number of times requiring cardiopulmonary resuscitation

    Compare the number of times requiring cardiorespiratory resuscitation with self-inflating bag in the context of apnea pause or severe desaturation in the period of time that customized 3D printed nasal mask (3DM) is used versus traditional nasal mask (TM).

    Time frame: 7 days

  4. Appearance of cutaneous lesions in nasal region or mucosa

    To compare the appearance of cutaneous lesions in the nasal region or nasal mucosa as a consequence of the pressure exerted by any of the masks, indicating the location and degree of the wound in the period of time that customized 3D printed nasal mask (3DM) is used versus traditional nasal mask (TM).

    Time frame: 7 days

  5. Pain assessment with scoring scale.

    To compare the degrees of pain, measured in the neonatal pain scale PIPP-R (Premature Infant Pain Profile-Revised), obtained every 12 hours in the period of time that customized 3D printed nasal mask (3DM) is used versus traditional nasal mask (TM). Regarding the PIPP-R scale, the minimum score is 1 and the maximum is 21. Scores between 1-6 correspond to mild pain, 7-11 moderate pain, and 12-21 severe pain.

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Al-Ramahi J, Luo H, Fang R, Chou A, Jiang J, Kille T. Development of an Innovative 3D Printed Rigid Bronchoscopy Training Model. Ann Otol Rhinol Laryngol. 2016 Dec;125(12):965-969. doi: 10.1177/0003489416667742. Epub 2016 Sep 7. PubMed 27605436 ↗
  • Zheng J, He H, Kuang W, Yuan W. Presurgical nasoalveolar molding with 3D printing for a patient with unilateral cleft lip, alveolus, and palate. Am J Orthod Dentofacial Orthop. 2019 Sep;156(3):412-419. doi: 10.1016/j.ajodo.2018.04.031. PubMed 31474271 ↗
  • Hadeed K, Dulac Y, Acar P. Three-dimensional printing of a complex CHD to plan surgical repair. Cardiol Young. 2016 Oct;26(7):1432-4. doi: 10.1017/S1047951116000755. Epub 2016 Jun 20. PubMed 27321706 ↗
  • Xu JJ, Luo YJ, Wang JH, Xu WZ, Shi Z, Fu JZ, Shu Q. Patient-specific three-dimensional printed heart models benefit preoperative planning for complex congenital heart disease. World J Pediatr. 2019 Jun;15(3):246-254. doi: 10.1007/s12519-019-00228-4. Epub 2019 Feb 22. PubMed 30796731 ↗
  • Zhao H, Lin G, Seong YH, Shi J, Xu J, Huang W. Anthropometric research of congenital auricular deformities for newborns. J Matern Fetal Neonatal Med. 2019 Apr;32(7):1176-1183. doi: 10.1080/14767058.2017.1402877. Epub 2017 Dec 8. PubMed 29219007 ↗
  • Minocchieri S, Burren JM, Bachmann MA, Stern G, Wildhaber J, Buob S, Schindel R, Kraemer R, Frey UP, Nelle M. Development of the premature infant nose throat-model (PrINT-Model): an upper airway replica of a premature neonate for the study of aerosol delivery. Pediatr Res. 2008 Aug;64(2):141-6. doi: 10.1203/PDR.0b013e318175dcfa. PubMed 18391845 ↗
  • Saugstad OD, Aune D. Optimal oxygenation of extremely low birth weight infants: a meta-analysis and systematic review of the oxygen saturation target studies. Neonatology. 2014;105(1):55-63. doi: 10.1159/000356561. Epub 2013 Nov 15. PubMed 24247112 ↗
  • Stenson BJ. Oxygen targets for preterm infants. Neonatology. 2013;103(4):341-5. doi: 10.1159/000349936. Epub 2013 May 31. PubMed 23736013 ↗
  • Bose CL, Dammann CE, Laughon MM. Bronchopulmonary dysplasia and inflammatory biomarkers in the premature neonate. Arch Dis Child Fetal Neonatal Ed. 2008 Nov;93(6):F455-61. doi: 10.1136/adc.2007.121327. Epub 2008 Aug 1. PubMed 18676410 ↗
  • Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A, Plavka R, Roehr CC, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GHA, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. Neonatology. 2019;115(4):432-450. doi: 10.1159/000499361. Epub 2019 Apr 11. PubMed 30974433 ↗
  • Sweet DG, Carnielli VP, Greisen G, Hallman M, Klebermass-Schrehof K, Ozek E, Te Pas A, Plavka R, Roehr CC, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GHA, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update. Neonatology. 2023;120(1):3-23. doi: 10.1159/000528914. Epub 2023 Feb 15. PubMed 36863329 ↗
  • Roh S, Parekh DP, Bharti B, Stoyanov SD, Velev OD. 3D Printing by Multiphase Silicone/Water Capillary Inks. Adv Mater. 2017 Aug;29(30). doi: 10.1002/adma.201701554. Epub 2017 Jun 7. PubMed 28590510 ↗
  • Hinton TJ, Hudson A, Pusch K, Lee A, Feinberg AW. 3D Printing PDMS Elastomer in a Hydrophilic Support Bath via Freeform Reversible Embedding. ACS Biomater Sci Eng. 2016 Oct 10;2(10):1781-1786. doi: 10.1021/acsbiomaterials.6b00170. Epub 2016 May 4. PubMed 27747289 ↗
  • Bhattacharjee N, Parra-Cabrera C, Kim YT, Kuo AP, Folch A. Desktop-Stereolithography 3D-Printing of a Poly(dimethylsiloxane)-Based Material with Sylgard-184 Properties. Adv Mater. 2018 May;30(22):e1800001. doi: 10.1002/adma.201800001. Epub 2018 Apr 14. PubMed 29656459 ↗
  • Clarke A, Yeomans E, Elsayed K, Medhurst A, Berger P, Skuza E, Tan K. A randomised crossover trial of clinical algorithm for oxygen saturation targeting in preterm infants with frequent desaturation episodes. Neonatology. 2015;107(2):130-6. doi: 10.1159/000368295. Epub 2014 Dec 12. PubMed 25531240 ↗
  • Duong K, Glover J, Perry AC, Olmstead D, Ungrin M, Colarusso P, MacLean JE, Martin AR. Feasibility of three-dimensional facial imaging and printing for producing customised nasal masks for continuous positive airway pressure. ERJ Open Res. 2021 Feb 1;7(1):00632-2020. doi: 10.1183/23120541.00632-2020. eCollection 2021 Jan. PubMed 33569497 ↗
  • Kamath AA, Kamath MJ, Ekici S, Stans AS, Colby CE, Matsumoto JM, Wylam ME. Workflow to develop 3D designed personalized neonatal CPAP masks using iPhone structured light facial scanning. 3D Print Med. 2022 Aug 1;8(1):23. doi: 10.1186/s41205-022-00155-7. PubMed 35913689 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 32 months is above that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2023
First posted
Jan 25, 2024
StartActual
Apr 16, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06224816
Lead sponsor
Hospital Universitario 12 de Octubre
Collaborators
ISCIII
Responsible party
María Teresa Moral Pumarega (Associate Professor of Pediatrics at the Complutense University of Madrid (UCM), Hospital Universitario 12 de Octubre) — Principal investigator
First posted
Jan 25, 2024
Start date
Apr 16, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 18, 2024

Study contacts

María Teresa Moral Pumarega
Contact
mmoralp@salud.madrid.org
649921733 ext. +34
María Teresa Moral Pumarega
principal investigator · Hospital Universitario 12 de Octubre
Antonio Martín González, Mechanical Engineering
study chair · Hospital Universitario 12 de Octubre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion